How long does Wegovy take to start working?
Initial loss within 4-6 weeks; titration to 2.4 mg over 16-20 weeks.
What is the maintenance dose?
2.4 mg weekly; sometimes 1.7 mg for patients who can't tolerate 2.4 mg.
Should my dose be higher than 2.4 mg?
No; 2.4 mg is the maximum approved dose.
Why did I lose quickly then stop?
The biological plateau pattern; metabolic adaptation defends new weight.
Do I need to track calories?
Not necessarily; can be useful for diagnosing compensation patterns.
Can stress prevent weight loss?
Yes; chronic stress elevates cortisol and drives emotional eating.
What if I'm losing inches but not pounds?
Body composition change; muscle gain and fat loss can mask scale change.
Should I switch to tirzepatide?
Discuss with prescriber; tirzepatide produces higher mean weight loss in trials.
Can long-term Wegovy use stop working?
Tolerance is not well-documented; continued use typically maintains loss.
- Why Am I Not Losing Weight on Ozempic? The Six Causes Worth Investigating
- Why Am I Not Losing Weight on Mounjaro? Plateau Patterns and Real Causes
- Why Am I Not Losing Weight on Zepbound? Plateau Realities and Course Correction
- Why Am I Not Losing Weight on Semaglutide? Brand and Compounded Considerations
- Why Am I Not Losing Weight on Tirzepatide? Decoding Stalled Progress
- Not Losing Weight on Ozempic: A Troubleshooting Checklist
Sources
- Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," NEJM, March 2021 (STEP 1)
- Rubino D et al., "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance," JAMA, April 2021 (STEP 4)
- Wegovy FDA prescribing information
- Tasali E et al., JAMA Internal Medicine, March 2022
- American Thyroid Association screening guidelines
- CDC alcohol use guidelines
- National Sleep Foundation duration recommendations
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.
Platform Disclaimer. FormBlends connects patients with licensed clinicians. This article is educational and does not replace individual clinical assessment. Discuss specific situations with your prescriber.
Compounded Medication Notice. Compounded semaglutide is prepared by 503A pharmacy partners for individual patients with documented clinical justification. Not FDA-approved. STEP trial data applies to brand Wegovy specifically.
Results Disclaimer. Individual outcomes vary. STEP 1 reported a 14.9% mean weight loss at week 68 with semaglutide 2.4 mg; the distribution included high responders and modest responders. Your result depends on dose, adherence, baseline weight, lifestyle, and physiology.
Trademark Notice. Wegovy, Ozempic, and NovoCare are trademarks or service marks of Novo Nordisk A/S. FormBlends is independent.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →